NeoGenomics, Inc. (NASDAQ:NEO) Position Reduced by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 6.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,165,063 shares of the medical research company's stock after selling 438,117 shares during the period. Janus Henderson Group PLC owned approximately 4.80% of NeoGenomics worth $101,600,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in NEO. PNC Financial Services Group Inc. boosted its position in shares of NeoGenomics by 5.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company's stock worth $257,000 after buying an additional 770 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of NeoGenomics by 6.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,339 shares of the medical research company's stock valued at $220,000 after purchasing an additional 863 shares in the last quarter. Blue Trust Inc. grew its position in shares of NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after purchasing an additional 1,103 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of NeoGenomics in the fourth quarter valued at approximately $26,000. Finally, KBC Group NV increased its stake in shares of NeoGenomics by 44.7% during the 4th quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock worth $108,000 after purchasing an additional 2,027 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Warren Stone acquired 5,700 shares of the company's stock in a transaction dated Monday, May 12th. The shares were bought at an average price of $8.58 per share, for a total transaction of $48,906.00. Following the completion of the purchase, the chief operating officer now directly owns 108,280 shares of the company's stock, valued at approximately $929,042.40. This trade represents a 5.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Lynn A. Tetrault purchased 7,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were purchased at an average cost of $8.14 per share, for a total transaction of $56,980.00. Following the purchase, the director now directly owns 7,000 shares in the company, valued at $56,980. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 65,600 shares of company stock valued at $512,438. 2.40% of the stock is currently owned by corporate insiders.

NeoGenomics Trading Up 3.4%

NASDAQ:NEO traded up $0.27 during trading hours on Friday, reaching $8.11. 1,257,184 shares of the company were exchanged, compared to its average volume of 1,123,626. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.12. The stock has a 50 day simple moving average of $9.07 and a 200 day simple moving average of $12.94. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -13.08 and a beta of 1.60. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The firm had revenue of $168.04 million for the quarter, compared to analysts' expectations of $171.38 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. NeoGenomics's revenue was up 7.6% on a year-over-year basis. During the same period last year, the firm posted ($0.02) EPS. As a group, analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on NEO. Leerink Partners cut NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $25.00 to $9.00 in a report on Wednesday, April 30th. The Goldman Sachs Group decreased their price objective on NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Morgan Stanley dropped their price objective on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a research report on Thursday, May 1st. Piper Sandler set a $12.00 target price on shares of NeoGenomics and gave the company an "overweight" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC lowered their price target on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a report on Tuesday, April 29th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $13.83.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.